TAVI to treat bicuspid AS

State-of-the-Art

Nov 18
TAVI to treat bicuspid AS
Didier Tchétché, Ole De Backer, et al.
This review explores the use of transcatheter aortic valve implantation (TAVI) for the treatment of bicuspid aortic valve (BAV) disease, highlighting the challenges, current knowledge, and future research needs.
free

Simultaneous Publication

Nov 16
Intrepid Transapical TMVR 5-Year Outcomes
Gilbert H.L. Tang, Michael J. Reardon, et al.

The key findings from this 5-year study of the early-generation Intrepid transapical transcatheter mitral valve replacement system were sustained mitral regurgitation reduction, durable hemodynamic valve performance, and improved functional status among survivors, despite high mortality rates.

Intrepid Transapical TMVR 5-Year Outcomes
free

Simultaneous Publication

Nov 16
Biomimetic balloon-expandable transcatheter heart valve in small aortic annuli
Ole De Backer, Vinayak N. Bapat, et al.

This study found that the novel DurAVR transcatheter heart valve demonstrated promising 30-day clinical and echocardiographic outcomes, including a low rate of prosthesis-patient mismatch, in patients with small aortic annuli.

Biomimetic balloon-expandable transcatheter heart valve in small aortic annuli
free

PCRLV2025

Nov 15
EuroIntervention at PCR London Valves 2025

The EuroIntervention team and Editors will be present at PCR London Valves 2025. Don’t miss out on the latest updates from the Journal and the first Alain Cribier Award Ceremony!

EuroIntervention at PCR London Valves 2025

new issue

Nov 14
New issue - PCR London Valves edition

A State-of-the-Art on TAVI in biscuspid aortic stenosis; an expert consensus on transcatheter tricuspid valve interventions in patients with transvalvular right ventricular leads; the ACURATE platform discontinuation; coronary cannulation after transfemoral TAVI with the Evolut FX; HALT after TAVI with the SAPIEN Ultra RESILIA; impact of aortic annular size on long-term outcomes and valve durability; the TRICURE first-in-human study; 5-year follow-up of EVOQUE TTVR; and more

New issue - PCR London Valves edition

Research Correspondence

Nov 13
Renal denervation and kidney disease
Verdiana Galli, Flavio Ribichini, et al.
This single-center study found that renal denervation was safe and effective in selected chronic kidney disease patients, with a potential slowing of kidney function decline.
Renal denervation and kidney disease

Editorial

Nov 12
Seeking the long-view
Tom Adriaenssens, Pascal Frederiks
This subanalysis of the OCCUPI Trial found that OCT guidance reduced the primary endpoint in acute coronary syndrome patients, but not in chronic coronary syndrome patients.
free

Original Research

Nov 11
ACS substudy of the OCCUPI Trial
Yong-Joon Lee, Byeong-Keuk Kim, et al.
In ACS patients with complex lesions, OCT-guided PCI demonstrated a lower risk of 1-year MACE compared to angiography-guided PCI, particularly in those who achieved stent optimization by OCT.
ACS substudy of the OCCUPI Trial
Turning Point Podcast Listen now


EVOQUE TTVR follow-up

Flashlight

Nov 18
EVOQUE TTVR follow-up
Kevin Millar, John G. Webb, et al.

Subscribe banner

Trial Design

Nov 10
Rationale and design of the PROTECT IV trial
Norman Mangner, Gregg W. Stone, et al.
This content discusses the various interventions used by cardiologists to diagnose, treat, and manage cardiovascular conditions, including coronary, valvular, heart failure, peripheral, hypertension, and stroke interventions.
Rationale and design of the PROTECT IV trial
free

Ahead of print

Nov 7
AF following PFO closure using ICM
Paul Gautier, Meyer Elbaz, et al.

This study found a high incidence of asymptomatic and paroxysmal atrial fibrillation following patent foramen ovale closure, with a significant proportion of episodes occurring beyond 30 days post-procedure.

AF following PFO closure using ICM
open access

Editorial

Nov 7
From evidence to practice
Adnan Kastrati, Fiorenzo Simonetti
This study replicated the findings of the ISAR-REACT 5 trial, showing that prasugrel was associated with a lower risk of the composite endpoint of all-cause death, myocardial infarction, or stroke compared to ticagrelor in patients with acute coronary syndrome.
From evidence to practice
free

Original Research

Nov 6
Routine prasugrel or ticagrelor use in MI
Mia Ravn Jacobsen, Rikke Sørensen, et al.
This study found that in Denmark, a national shift from ticagrelor to prasugrel occurred in MI patients treated with PCI between 2019-2022, and prasugrel was associated with reduced rates of MACE and MI compared to ticagrelor, with no difference in bleeding.
Routine prasugrel or ticagrelor use in MI

Flashlight

Nov 5
Concertina effect mimicking plaque rupture on OCT
Nitin Chandra Mohan, Thomas W. Johnson
A 73-year-old female with a history of cardiac conditions presented with chest pain and elevated troponin. Coronary angiography and optical coherence tomography revealed a 'concertina effect' in the obtuse marginal branch, which resolved upon guidewire withdrawal.
Concertina effect mimicking plaque rupture on OCT

Original Research

Nov 4
Blood pressure changes following renal denervation
Roland E. Schmieder, Michael Böhm, et al.
This study found that higher baseline systolic blood pressure is associated with greater blood pressure reduction at 6 months following radiofrequency renal denervation in patients with uncontrolled hypertension.
Blood pressure changes following renal denervation
open access

Receive our newsletter

PCR
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved